The main purpose of SUNRISE-CRC is to determine whether treatment with a high dose of sunitinib provides a better chance of survival and slows the progression of (colo)rectal cancer (CRC) more than standard treatment with TAS-102. Sunitinib, at a low daily dose, has been approved as a treatment for kidney cancer, but not yet for colorectal and rectal cancer. The standard treatment for metastatic colorectal or rectal cancer in this line is TAS-102, a form of chemotherapy. This study also examines whether certain proteins or other characteristics can be detected in the patient's blood and tumor that are predictive of the effect of the treatment. The biomaterial and associated clinical data are being collected and stored in the SUNRISE-CRC biobank.
Want to know more about these subjects? Click on the buttons below for more news.
Related news items
Dutch-Nordic Alliance for Precision Cancer Medicine launched26 November 2021
The Nordic countries (Denmark, Sweden, Norway, and Finland) are together setting up national clinical precision cancer trials modelled on the very successful DRUP trial in the Netherlands.read more
New Automated PBMC isolation method introduced in LMI.21 September 2021
The Radboud Biobank (RB) and the laboratory of Medical Immunology (LMI) are making plans to replace the density gradient centrifugation method with a new automated PBMC isolation method, the AutoMACS Pro Separator.read more
Lysine Metabolism sub-biobank21 September 2021
Hereditary metabolic disorders form a large group of more than 1,400 rare disorders in which an error in the DNA causes abnormalities in the process in which proteins, fats and carbohydrates are converted into smaller building materials and energy.read more